A Phase 1, Randomized, Subject- And Investigator Blind, Sponsor Open, Placebo Controlled, Single- And Multiple-Dose Escalation Study Of PF-04171327 In Healthy Adult Japanese And Western Subjects In Fasting And Fed Conditions.
Phase of Trial: Phase I
Latest Information Update: 26 Oct 2016
At a glance
- Drugs Fosdagrocorat (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 26 Oct 2016 Results published in the International Journal of Clinical Pharmacology and Therapeutics.
- 30 Oct 2013 Results for adult Japanese volunteers administered PF 4171327 20mg for 12 days in the fasted state presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 15 Aug 2011 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.